Top

Published in:

01-09-2014 | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Recent Advances in Visualizing Vulnerable Plaque: Focus on Noninvasive Molecular Imaging

Authors: Gezim Bala, Bernard Cosyns

Published in: Current Cardiology Reports | Issue 9/2014

Abstract

Traditional imaging methods in atherosclerosis have focused primarily on anatomic information. Imaging approaches that visualize molecular targets rather than anatomic structures may emphasize biologic aspects of atherosclerosis. Molecular imaging of atherosclerotic lesions has become a crucial experimental tool and is now emerging in the clinical arena. In this review, we briefly highlight the rationale and fundamental principles of molecular imaging. We then discuss the promising imaging modalities, along with their potential limitations, and the molecular targets being investigated in experimental research. Finally, we summarize the most important clinical studies recently performed in humans.

Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics‚ 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–97. doi:10.1161/CIR.0b013e3182456d46.PubMedCrossRef

Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83(1):356–62. doi:10.1161/01.cir.83.1.356.PubMedCrossRef

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003. doi:10.1016/s0195-668x(03)00114-3.PubMedCrossRef

Zarich S, Luciano C, Hulford J, Abdullah A. Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham Risk Score underestimate cardiovascular risk in this population? Diabetes Vasc Dis Res. 2006;3(2):103–7. doi:10.3132/dvdr.2006.012.CrossRef

Kalantzi K, Korantzopoulos P, Tzimas P, Katsouras CS, Goudevenos JA, Milionis HJ. The relative value of metabolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. Am Heart J. 2008;155(3):534–40. doi:10.1016/j.ahj.2007.10.038.PubMedCrossRef

Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahlmonsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary-artery disease and the development of myocardial-infarction. J Am Coll Cardiol. 1988;12(1):56–62.PubMedCrossRef

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108(14):1664–72. doi:10.1161/01.cir.0000087480.94275.97.PubMedCrossRef

Suh WM, Seto AH, Margey RJ, Cruz-Gonzalez I, Jang IK. Intravascular detection of the vulnerable plaque. Circ Cardiovasc Imaging. 2011;4(2):169–78. doi:10.1161/CIRCIMAGING.110.958777.PubMedCrossRef

Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35. doi:10.1056/NEJMoa1002358.PubMedCrossRef

10.

Nesto RW, Waxman S, Mittleman DMA, Sassower MA, Fitzpatrick PJ, Lewis SM, et al. Angioscopy of culprit coronary lesions in unstable angina pectoris and correlation of clinical presentation with plaque morphology. Am J Cardiol. 1998;81(2):225–8. doi:10.1016/S0002-9149(97)00889-8.PubMedCrossRef

11.

Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed tomography. Eur Heart J. 2010;31(12):1442–8. doi:10.1093/eurheartj/ehq150.PubMedCrossRef

12.

Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13(5):636–41. doi:10.1038/Nm1571.PubMedCrossRef

13.

Villanueva FS, Wagner WR. Ultrasound molecular imaging of cardiovascular disease. Nat Clin Pract Cardiovasc. 2008;5:S26–32. doi:10.1038/Ncpcardio1246.CrossRef

14.

Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17(12):1680–4. doi:10.1038/Nm.2555.PubMedCentralPubMedCrossRef

15.

Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30(7):1282–92. doi:10.1161/atvbaha.108.179739.PubMedCrossRef

16.

Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451(7181):953–7. doi:10.1038/nature06803.PubMedCrossRef

17.

Hartung D, Petrov A, Haider N, Fujimoto S, Blankenberg F, Fujimoto A, et al. Radiolabeled monocyte chemotactic protein 1 for the detection of inflammation in experimental atherosclerosis. J Nucl Med. 2007;48(11):1816–21. doi:10.2967/jnumed.107.043463.PubMedCrossRef

18.

Ohtsuki K, Hayase M, Akashi K, Kopiwoda S, Strauss HW. Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions. Circulation. 2001;104(2):203–8. doi:10.1161/01.cir.104.2.203.PubMedCrossRef

19.

Hamilton AJ, Huang SL, Warnick D, Rabbat M, Kane B, Nagaraj A, et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol. 2004;43(3):453–60. doi:10.1016/j.jacc.2003.07.048.PubMedCrossRef

20.

Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116(3):276–84. doi:10.1161/circulationaha.106.684738.PubMedCrossRef

21.

Broisat A, Hernot S, Toczek J, De Vos J, Riou LM, Martin S, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110(7):927–37. doi:10.1161/circresaha.112.265140.PubMedCentralPubMedCrossRef

22.

Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96(3):327–36. doi:10.1161/01.RES.0000155722.17881.dd.PubMedCrossRef

23.

Broisat A, Riou LM, Ardisson V, Boturyn D, Dumy P, Fagret D, et al. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p. Eur J Nucl Med Mol Imaging. 2007;34(6):830–40. doi:10.1007/s00259-006-0310-4.PubMedCrossRef

24.

McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28(1):77–83. doi:10.1161/atvbaha.107.145466.PubMedCentralPubMedCrossRef

25.

Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114(14):1504–11. doi:10.1161/circulationaha.106.646380.PubMedCrossRef

26.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43. doi:10.1161/hc0902.104353.PubMedCrossRef

27.

Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116(9):1052–61. doi:10.1161/circulationaha.106.647164.PubMedCrossRef

28.

Kooi ME, Cappendijk VC, Cleutjens KBJM, Kessels AGH, Kitslaar PJEHM, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107(19):2453–8. doi:10.1161/01.cir.0000068315.98705.cc.PubMedCrossRef

29.

Tang T, Howarth SPS, Miller SR, Trivedi R, Graves MJ, King-Im JU, et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006;37(9):2266–70. doi:10.1161/01.str.0000236063.47539.99.PubMedCrossRef

30.

Hyafil F, Cornily J-C, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13(5):636–41. http://www.nature.com/nm/journal/v13/n5/suppinfo/nm1571_S1.html.PubMedCrossRef

31.

Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117(3):379–87. doi:10.1161/circulationaha.107.741181.PubMedCentralPubMedCrossRef

32.

Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11. doi:10.1161/01.cir.0000020548.60110.76.PubMedCrossRef

33.

Davies JR, Rudd JHF, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36(12):2642–7. doi:10.1161/01.STR.0000190896.67743.b1.PubMedCrossRef

34.

Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24. doi:10.1016/j.jacc.2006.05.076.PubMedCrossRef

35.

Matter CM, Wyss MT, Meier P, Spath N, von Lukowicz T, Lohmann C, et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol. 2006;26(3):584–9. doi:10.1161/01.ATV.0000200106.34016.18.PubMedCrossRef

36.

Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, et al. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med. 2014;20(2):215–9. doi:10.1038/nm.3437.PubMedCrossRef

37.

Hansson GRK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. doi:10.1056/NEJMra043430.PubMedCrossRef

38.

Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006;26(8):1702–11. doi:10.1161/01.atv.0000229218.97976.43.PubMedCrossRef

39.

Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JGS, Weinreb DB, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci. 2007;104(3):961–6. doi:10.1073/pnas.0606281104.PubMedCentralPubMedCrossRef

40.

Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M, Takai N, et al. Targeting of lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med. 2008;49(10):1677–85. doi:10.2967/jnumed.107.049536.PubMedCrossRef

41.

Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang B-Y, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010;3(4):464–72. doi:10.1161/circimaging.109.896654.PubMedCentralPubMedCrossRef

42.

Laufer EM, Winkens MHM, Corsten MF, Reutelingsperger CPM, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled annexin A5. Q J Nucl Med Mol Imaging. 2009;53(1):26–34.PubMed

43.

Chen J, Tung C-H, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105(23):2766–71. doi:10.1161/01.cir.0000017860.20619.23.PubMedCrossRef

44.

Deguchi J-O, Aikawa M, Tung C-H, Aikawa E, Kim D-E, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114(1):55–62. doi:10.1161/circulationaha.106.619056.PubMedCrossRef

45.

Jaffer FA, Kim D-E, Quinti L, Tung C-H, Aikawa E, Pande AN, et al. Optical visualization of cathepsin k activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007;115(17):2292–8. doi:10.1161/circulationaha.106.660340.PubMedCrossRef

46.

Lancelot E, Amirbekian V, Brigger IN, Raynaud J-SB, Ballet SB, David C, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 2008;28(3):425–32. doi:10.1161/atvbaha.107.149666.PubMedCrossRef

47.

Haider N, Hartung D, Fujimoto S, Petrov A, Kolodgie F, Virmani R, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol. 2009;16(5):753–62. doi:10.1007/s12350-009-9107-8.PubMedCentralPubMedCrossRef

48.

Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med. 2011;52(11):1795–802. doi:10.2967/jnumed.111.092379.PubMedCentralPubMedCrossRef

49.

Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–61. doi:10.1161/01.atv.0000178991.71605.18.PubMedCrossRef

50.

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108(18):2270–4. doi:10.1161/01.cir.0000093185.16083.95.PubMedCrossRef

51.

Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2(4):331–8. doi:10.1161/circimaging.108.846865.PubMedCrossRef

52.

Heroux J, Gharib A, Danthi N, Cecchini S, Ohayon J, Pettigrew R. High-affinity Œ±vŒ≤3 integrin targeted optical probe as a new imaging biomarker for early atherosclerosis: initial studies in Watanabe rabbits. Mol Imaging Biol. 2010;12(1):2–8. doi:10.1007/s11307-009-0242-z.PubMedCrossRef

53.

Botnar RM, Buecker A, Wiethoff AJ, Parsons EC, Katoh M, Katsimaglis G, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110(11):1463–6. doi:10.1161/01.cir.0000134960.31304.87.PubMedCrossRef

54.

Spuentrup E, Botnar R, Wiethoff A, Ibrahim T, Kelle S, Katoh M, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18(9):1995–2005. doi:10.1007/s00330-008-0965-2.PubMedCrossRef

55.

Jaffer FA, Tung C-H, Wykrzykowska JJ, Ho N-H, Houng AK, Reed GL, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation. 2004;110(2):170–6. doi:10.1161/01.cir.0000134484.11052.44.PubMedCrossRef

56.

Tei L, Mazooz G, Shellef Y, Avni R, Vandoorne K, Barge A, et al. Novel MRI and fluorescent probes responsive to the factor XIII transglutaminase activity. Contrast Media Mol Imaging. 2010;5(4):213–22. doi:10.1002/cmmi.392.PubMedCrossRef

57.

Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26(4):314–9.PubMedCrossRef

58.

Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50(10):1611–20. doi:10.2967/jnumed.109.065151.PubMedCrossRef

59.

Grandpierre SN, Desandes E, Meneroux B, Djaballah W, Mandry D, Netter F, et al. Arterial foci of F-18 fluorodeoxyglucose are associated with an enhanced risk of subsequent ischemic stroke in cancer patients: a case-control pilot study. Clin Nucl Med. 2011;36(2):85–90. doi:10.1097/RLU.0b013e318203bb42.PubMedCrossRef

60.••

Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71(5):709–18. doi:10.1002/ana. In symptomatic carotid stenosis, inflammation-related FDG uptake was associated with early stroke recurrence, independent of the degree of stenosis.PubMedCrossRef

61.

Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519–30.PubMedCentralPubMedCrossRef

62.

Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation—evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48(9):1825–31. doi:10.1016/J.Jacc.2006.03.069.PubMedCrossRef

63.•

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17. doi:10.1016/j.jacc.2013.04.066. Dose-dependent anti-inflammatory effects of statin therapy evaluated by 8F-FDG PET/CT carotid plaque imaging.PubMedCrossRef

64.•

Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59. Molecular–structural assessment of dalcetrapib on carotid atherosclerosis using 18F-FDG PET/CT and anatomical MR imaging.PubMedCrossRef

65.

Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes: a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. J Am Coll Cardiol Img. 2011;4(10):1110–8. doi:10.1016/j.jcmg.2011.08.007.

66.

Elkhawad M, Rudd JHF, Sarov-Blat L, Cai G, Wells R, Davies LC, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. J Am Coll Cardiol Img. 2012;5(9):911–22. doi:10.1016/j.jcmg.2012.02.016.

67.

Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50(4):563–8. doi:10.2967/jnumed.108.055616.PubMedCrossRef

68.

Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. J Am Coll Cardiol Img. 2010;3(4):388–97. doi:10.1016/j.jcmg.2010.01.004.

69.

Hiari N, Rudd JH. FDG PET imaging and cardiovascular inflammation. Curr Cardiol Rep. 2011;13(1):43–8. doi:10.1007/s11886-010-0150-5.PubMedCrossRef

70.

Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. COronary artery calcium score combined with framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210–5. doi:10.1001/jama.291.2.210.PubMedCrossRef

71.•

Dweck MR, Chow MWL, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59(17):1539–48. doi:10.1016/j.jacc.2011.12.037. This is the first study to describe 18F-NaF PET/CT imaging of active plaque calcification in the coronary arteries.PubMedCrossRef

72.

Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51(6):862–5. doi:10.2967/jnumed.110.076471.PubMedCrossRef

73.

Derlin T, Wisotzki C, Richter U, Apostolova I, Bannas P, Weber C, et al. In vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factors. J Nucl Med. 2011;52(3):362–8. doi:10.2967/jnumed.110.081208.PubMedCrossRef

74.

Derlin T, Tóth Z, Papp LS, Wisotzki C, Apostolova I, Habermann CR, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med. 2011;52(7):1020–7. doi:10.2967/jnumed.111.087452.PubMedCrossRef

75.••

Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2013;383(9918):705–13. doi:10.1016/S0140-6736(13)61754-7. 18F-NaF PET/CT imaging study demonstrating higher 18F-NaF uptake in culprit lesions of patients with acute coronary syndrome.PubMedCrossRef

76.

Gaemperli O, Shalhoub J, Owen DRJ, Lamare F, Johansson S, Fouladi N, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J. 2012;33(15):1902–10. doi:10.1093/eurheartj/ehr367.PubMedCrossRef

77.

Trivedi RA, Mallawarachi C, U-King-Im J-M, Graves MJ, Horsley J, Goddard MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26(7):1601–6. doi:10.1161/01.ATV.0000222920.59760.df.PubMedCrossRef

78.

Tang TY, Howarth SPS, Miller SR, Graves MJ, Patterson AJ, U-King-Im J-M, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53(22):2039–50. doi:10.1016/j.jacc.2009.03.018.PubMedCrossRef

79.

Mittleman MA, Mostofsky E. Physical, psychological and chemical triggers of acute cardiovascular events: preventive strategies. Circulation. 2011;124(3):346–54. doi:10.1161/circulationaha.110.968776.PubMedCentralPubMedCrossRef

80.

Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R. PLaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA. 1999;281(10):921–6. doi:10.1001/jama.281.10.921.PubMedCrossRef

Title: Recent Advances in Visualizing Vulnerable Plaque: Focus on Noninvasive Molecular Imaging
Authors: Gezim Bala
Bernard Cosyns
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 9/2014
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-014-0520-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recent Advances in Visualizing Vulnerable Plaque: Focus on Noninvasive Molecular Imaging

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Catheter Ablation for Premature Ventricular Contractions and Ventricular Tachycardia in Patients with Heart Failure

Childhood Infections and Trauma as Risk Factors for Stroke

The Evaluation and Treatment of Endocrine Forms of Hypertension

An Update on Stem Cell Therapies for Acute Coronary Syndrome

Cerebral Venous Sinus Thrombosis: Update on Diagnosis and Management

Dolichoectasia and the Risk of Stroke and Vascular Disease: A Critical Appraisal